BioPharma Resources

Drug Trial Radar · NCT05152147

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 920 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

920

Actual

Start

Dec 2, 2021

Primary completion

Jul 15, 2026

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
Collaborators
BeOne Medicines LTD; BeOne Pharmaceutical Co., Ltd.
First posted
Dec 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy. The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).

Conditions

  • Gastric Neoplasms
  • Gastroesophageal Adenocarcinoma
  • Esophageal Adenocarcinoma

Interventions

  • ZanidatamabDrug

    Administered IV

  • TislelizumabDrug

    Administered IV

  • TrastuzumabDrug

    Administered intravenously (IV)

  • CapecitabineDrug

    Administered orally (PO bid)

  • OxaliplatinDrug

    Administered IV

  • CisplatinDrug

    Administered IV

  • 5-FluorouracilDrug

    Administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) by BICRTime frame: Up to 2.5 years
  2. Overall survivalTime frame: Up to 3.5 years

Locations

227 sites in 33 countries. Site status is shown where the registry gives one.

  • Hospital de Gastroenterología Dr Bonorino Udaondo

    Buenos Aires, Argentina

  • Instituto de Investigaciones Metabólicas - IDIM

    Buenos Aires, Argentina

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina

  • Fundación Centro de Medicina Nuclear y Molecular ER

    Córdoba, Argentina

  • Centro Médico Privado CEMAIC

    Córdoba, Argentina

  • Centro de Investigación Pergamino S.A.

    Pergamino, Argentina

  • Centro de Investigación Clínica - Clínica Viedma

    Viedma, Argentina

  • Flinders Medical Centre

    Bedford Park, Australia

  • Austin Health

    Heidelberg, Australia

  • Liverpool Hospital

    Liverpool, Australia

  • Fiona Stanley Hospital

    Murdoch, Australia

  • Imelda VZW

    Bonheiden, Belgium

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • UZ Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • CHU de Liège

    Liège, Belgium

  • Centro Integrado de Pesquisa - CIP

    Barretos, Brazil

  • Fundação Pio XII Hospital de Câncer de Barretos

    Barretos, Brazil

  • Cenantron - Centro Avancado de Tratamento Oncologico Ltda

    Belo Horizonte, Brazil

  • Centro de Pesquisas Clínicas/Fundação Doutor Amaral Carvalho

    Brasília, Brazil

  • Instituto Do Câncer Do Ceará ICC

    Fortaleza, Brazil

  • Hospital de Clinicas de Porto Alegre (HCPA) - PPDS

    Porto Alegre, Brazil

  • Irmandade Da Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Brazil

  • Hospital Nossa Senhora Da Conceição

    Porto Alegre, Brazil

  • Núcleo de Pesquisa Clínica da Rede São Camilo

    Santo André, Brazil

  • Instituto do Cancer do Estado de São Paulo ICESP

    São Paulo, Brazil

  • Instituto de Oncologia de Sorocaba

    Sorocaba, Brazil

  • Princess Margaret Cancer Centre

    Toronto, Canada

  • Centro de Estudios Clínicos SAGA SpA

    Providencia, Chile

  • Sociedad Oncovida S.A

    Santiago, Chile

  • Icegclinic

    Santiago, Chile

  • BIOCINETIC SpA

    Santiago, Chile

  • Sociedad de Investigaciones Medicas Limitada

    Temuco, Chile

  • Centro Internacional de Estudios Clinicos CIEC

    Santiago, Region Metropolitan, Chile

  • Fundación Arturo López Pérez (FALP) - PPDS

    Providencia, Santiago Metropolitan, Chile

  • Beijing Chao-Yang Hospital, Capital Medical University

    Beijing, China

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, China

  • Beijing Cancer Hospital

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • Beijing Luhe Hospital, Capital Medical University

    Beijing, China

Showing 40 of 227 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.